Grace Therapeutics, Inc.
GRCE· Nasdaq
GRCEGrace Therapeutics, Inc.
Filed Aug 13, 2026 · 10-Q · 44 days after period end · 0001140361-26-032632
| Metric | Q1 2027 | Q1 2026 | Q1 2025 | Q1 2024 |
|---|---|---|---|---|
| Net Income | -$15.79M | -$3.36M | -$2.62M | -$4.02M |
| EPS Diluted | -$0.91 | -$0.21 | -$0.24 | -$0.54 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 13, 2026 · 44 d after period end
